pSivida CEO to participate at glaucoma conference

pSivida (NASDAQ:PSDV; ASX:PVA) CEO Dr. Paul Ashton will participate today in a panel: New Horizons in Glaucoma Drug Delivery and IOP Monitoring during the Glaucoma 360 New Horizons forum at the Palace Hotel in San Francisco. The conference is being presented by the Glaucoma Research Foundation in association with Ophthalmology Times to bring together leaders [...]

Roth upgrades Antares Pharma to buy

Roth Capital Partners has upgraded Antares Pharma (AMEX:AIS) to “buy” from “neutral” and raised its 12-month price target to $3.50 from $2, saying the balance sheet is strong and the company could become cash flow positive this year. “The solid financial position, platform opportunities, and potential for advancement of key products make the stock attractive [...]

pSivida updates clinical programs

pSivida (NASDAQ:PSDV; ASX:PVA) in its first quarter (ended September 30) report updated its three clinical-stage product candidates for the treatment of back-of-the-eye diseases. The most advanced is Iluvien for diabetic macular edema (DME) being developed by licensee, Alimera Sciences, which has resubmitted a New Drug Application and is awaiting a response from the FDA. The [...]

Rodman sees higher small-cap biotech valuations

Citing the proposed acquisition of Anadys Pharmaceuticals (NASDAQ:ANDS) by Roche (NASDAQ: RHHBY) at a 260% premium, Rodman & Renshaw figures that Pharma’s strong balance sheet and expiring patents on blockbuster drugs “bring together the perfect storm of factors could lead to higher small-cap biotechnology valuations.” The Roche-Anadys acquisition highlights the “increasing appetite of pharmaceutical companies [...]

pSivida in orthopedics evaluation agreement

pSivida (NASDAQ:PSDV; ASX:PVA) has entered into an evaluation agreement with the Hospital for Special Surgery, a world leader in orthopedics, rheumatology and rehabilitation, to investigate pSivida’s bioerodible drug delivery technologies in orthopedic surgery. “We believe this orthopedic evaluation agreement is important for pSivida as our drug delivery technology, originally developed for ophthalmology, is being investigated [...]

Paladin eyes Mexico and Brazil for expansion

Pharmaceutical distributor Paladin Labs (TSX:PLB) has set its sights on moving into Mexico and Brazil as it continues its strategy of expanding internationally to complement its growth in Canada. “I would like to be in more geographies, and we’re keenly interested in Mexico and Brazil and looking to do something there,” CEO Jonathan Goodman says [...]

pSivida takes us on a fantastic voyage to the back of the eye

After developing several miniaturized, injectable drug delivery systems for the treatment of niche ocular diseases, pSivida (NASDAQ:PSDV; ASX:PVA) is now at the precipice of several blockbuster indications, including diabetic macular edema (DME), age-related macular degeneration (AMD) and glaucoma, with its next-generation Durasert device. And in early development is a new generation Tethadur platform that relies [...]

In conversation with Cheryl Reicin

There’s no bigger booster of life sciences than Cheryl Reicin, who heads the group practice at Torys LLP.  American-born, she moved to Torys in 2004 from McDermott Will & Emery of New York, where she chaired an 85-attorney life sciences group, the largest in the U.S.  Her corporate and securities practice focuses on biotech, medical [...]

In conversation with Dr. Simon Pimstone

As CEO of Xenon Pharmaceuticals, Dr. Simon Pimstone and his partners have led the closely held Vancouver company on a journey of developing novel drugs that target genetically defined targets.  By studying genes responsible for rare and inherited diseases, Xenon figures they represent highly validated intervention points for new medicines.  In other words, going from [...]

Protox gets credibility boost from Warburg Pincus

An equity injection of up to $35 million from private equity giant Warburg Pincus represents a huge vote of confidence in Protox Therapeutics (TSX:PRX) and its lead PRX302 drug for enlarged prostate or benign prostatic hyperplasia (BPH), with the drug potentially able to target two other diseases: prostate cancer and prostatitis. “We went through an [...]

Next Page »